Screener
Ionis Pharmaceuticals IONS EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Ionis Pharmaceuticals’s reported figures.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
FAQ
- What is Ionis Pharmaceuticals's EBITDA?
- Ionis Pharmaceuticals (IONS) reported EBITDA of -$98.16M in Q2 2026.
- How has Ionis Pharmaceuticals's EBITDA changed year-over-year?
- Ionis Pharmaceuticals's EBITDA decreased by 168.8% year-over-year, from $142.68M to -$98.16M.
- What is the long-term trend for Ionis Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's EBITDA has grown at a 133.8% compound annual growth rate (CAGR), from -$12.35M to -$369.24M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Ionis Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude